Sponsor-Investigators

David Potter

HCRN-HN02-40

A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Status

Closed

Cancer Types

Head and Neck

Locations